

**GUIDANCE for PRESCRIBING and ADMINISTRATION of
AS REQUIRED ORAL PSYCHOTROPIC MEDICATION in
MENTAL HEALTH & LEARNING DISABILITY INPATIENT SERVICES**



TARGET AUDIENCE	Nursing, medical and pharmacy staff working within Mental Health & Learning Disability inpatient services
PATIENT GROUP	Mental Health & Learning Disability Inpatient settings in NHS Lanarkshire

Clinical Guidelines Summary

The following guidance describes a good practice model for the use of as required oral psychotropic medication within all mental health and learning disability inpatient settings in NHS Lanarkshire.

Clinical judgement should be exercised on the applicability of any guideline, influenced by patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty. If there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

For use of psychotropic medication in the management of delirium, refer to local delirium guidance. ¹

Contents	Page
Introduction Legislation	2
Prescribing	3,4
Cost effective prescribing	4
Haloperidol – cautions, contraindications, recommendations	5
Pharmacokinetics	6
Administration Documentation	7
Review	8
References	9
Consultation/ Distribution and Governance information Change record	10

Introduction

The use of ‘*as required*’ or ‘*prn*’ (*pro re nata*) psychotropic medication during an inpatient stay within a mental health ward is a frequently used practice and an often valuable strategy for managing individuals with fluctuating mental state where nursing staff can administer medication at their discretion.

Local and national audit work however, has identified areas for improvement in the way that *as required* psychotropic medications are prescribed, administered, documented and reviewed.^{2,3,4}

Legislation

For individuals who are detained under the Mental Health (Care and Treatment (Scotland) Act 2003, careful consideration must be given prior to prescribing and administering any as required psychotropic medication to ensure that its use is authorised under the Act (i.e. where the patient has a T2 or T3 certificate, it specifies the intervention).

Any emergency treatment under the 2003 Act should be recorded on form T4. This will include treatment that is urgently necessary but is not covered by an existing T2 or T3 certificate. The T4 form should be used to notify the Mental Welfare Commission (MWC) of the administration of urgent treatment retrospectively.

For further advice, see the MWC’s Advice Notes on Medical Treatment under Part 16 and Consent to Treatment Good Practice Guide.^{5,6}

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on [www.nhs.uk/guidelines.scot.nhs.uk](http://www.nhs.uk/guidelines/scot.nhs.uk)

1. Prescribing

- 1.1 All prescriptions for *as required* psychotropic medication should be tailored to the individual patient.
- 1.2 The choice of *as required* psychotropic should be guided by the patient's presentation, their concurrent regular medication, previous response to treatment and any co-morbid physical health issues.
- 1.3 Any advance statement that addresses medication use should be taken into consideration prior to prescribing *as required* psychotropic medication.
- 1.4 *As required* psychotropic medications should not, as a rule, be prescribed routinely on admission. However, in areas with limited prescribing support, it may be appropriate to prescribe *as required* psychotropic medication on admission, if following assessment, this is deemed appropriate.
- 1.5 Prescriptions for *as required* psychotropic medications must state the following;⁷
- route of administration
 - dose
 - minimum dose interval
 - maximum dose that can be administered in 24 hours
 - clear indication for administration i.e. what symptoms are being targeted by the intervention
- 1.6 Consider the pharmacokinetic properties of *as required* psychotropic medication prior to prescribing. (**Table 1: Pharmacokinetics of oral psychotropic medication**)
- 1.7 Consider if the medication is prescribed via two routes (e.g. both oral and IM) and state the maximum cumulative dose.
- 1.8 High dose antipsychotic therapy (HDAT) may sometimes be used in an emergency for acute symptoms. This can happen, particularly, with the use of *as required* antipsychotics. Consider the patient's regular prescribed medication. Prescribers should be aware when prescribing *as required* medications, of inadvertently causing the potential for HDAT. This should be discussed with the consultant psychiatrist before this happens.⁸
- 1.9 When prescribing *as required* benzodiazepines, consider any existing prescription for a regular benzodiazepine in the context of tolerance and potential ineffectiveness. The sedative antihistamine, promethazine may be a useful alternative in these circumstances.

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

1. Prescribing *cont.*

1.10 Promethazine has strong anticholinergic effects e.g. urinary retention, constipation, tachycardia, blurred vision, impaired cognitive function, confusion, memory impairment and delirium. Promethazine can increase the anticholinergic burden of other regular medication increasing the risk of adverse effects. Extra caution should be taken when prescribing in the elderly, frail people, people with comorbidities and polypharmacy.

1.11 Benzodiazepines should be first line in antipsychotic-naïve patients, where there is a history of epilepsy or if there is a chance behaviour is related to seizure activity.

1.12 *As required* antipsychotics should not routinely be prescribed for antipsychotic-naïve patients.

1.13 The patient's regular antipsychotic *may* be an appropriate choice for *as required* use (e.g. olanzapine, quetiapine, risperidone, zuclopenthixol). Clozapine would be an exception to this advice and **must not** be used on an *as required* basis.

1.14 If haloperidol is prescribed *as required*, consider the patient's other prescribed medication and potentially contraindicated combinations. Where practical, an ECG should be undertaken prior to prescribing (see below).

1.15 An entry in the patient's clinical notes should be made detailing the reason for the prescription and providing further context for the indication.

1.16 At the earliest opportunity (usually at the first multidisciplinary team meeting), an individualised treatment plan should be developed to include suitable de-escalation techniques, oral *as required* psychotropic medications and where appropriate, IM psychotropic medications. For further information on use of IM medication refer to; [NHSL Guideline for IM medication for Acute Behavioural Disturbance](#)⁹

Cost effective prescribing


Where tolerated and clinically appropriate;

Risperidone doses under 1mg	<ul style="list-style-type: none"> • prescribe as oral liquid
Haloperidol doses under 2.5mg	<ul style="list-style-type: none"> • prescribe as oral liquid
Lorazepam dose of 500 micrograms	<ul style="list-style-type: none"> • prescribe as 1mg tablets (most generic tablets have a scoreline and can be halved).

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk

Haloperidol- cautions, contraindications and recommendations



Do not use haloperidol in the following situations:

- In Lewy body dementia or where it cannot be excluded
- In older adults (unless under specialist advice)
- In frail adults (unless under specialist advice)
- In learning disability (unless under specialist advice)
- In patients under 18 years of age
- If the patient is antipsychotic naïve
- If the cardiac status is unknown (need baseline ECG prior to haloperidol)
- If there is evidence of cardiovascular disease including prolonged QTc
- In combination with other drugs that can prolong the QTc interval
- Uncorrected hypokalaemia

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhs.uk/guidelines/scot.nhs.uk

Table 1: Pharmacokinetics of oral psychotropic medication ^{10,11}

Medication	Usual adult doses ^a	Max adult dose/ 24 hours ^c	Time to peak concentration (Tmax)	Elimination half-life (t1/2)
Lorazepam ^b	0.5-1mg	4mg	2 hours	10-20 hours
Diazepam	2-5mg	30mg	30-90 mins	24-48 hours ^d
Promethazine	25-50mg	100mg	2-3 hours	5-14 hours
Chlorpromazine ^e	25-50mg	1000mg	2-4 hours	30 hours
Haloperidol ^f	1.5-5mg	20mg ^g	2-6 hours	12-38 hours
Olanzapine	5mg	20mg	5-8 hours	30-38 hours
Quetiapine	25-50mg	750mg	1.5 hours	6-7 hours
Risperidone	500micrograms - 1 mg	16mg ^h	1-2 hours	19.5 hours

Footnotes

a. lower doses of medication should be used in older adults, those with co-morbid conditions, individuals of low body weight, patients under 18 years of age and adults with a learning disability (unless it has been established that standard doses are necessary and it is in accordance with the patient's individualised treatment plan)

b. lorazepam 1mg is approximately equivalent to 10mg diazepam.¹³

c. consider regular medication and the potential for exceeding the BNF maximum dose recommendations with the use of *as required* medication, especially in relation to antipsychotic prescribing and the potential for inadvertent high dose

d. active metabolite of diazepam has a half-life of 2-5 days

e. chlorpromazine is a potent antihistamine and sedative, but has a wide ranging effect on other receptors and can be poorly tolerated. In practical terms, its use should be reserved for a minority of patients who have a prior history of its use.

f. for information on the use of haloperidol in the management of delirium, refer to delirium guidance ¹

g. in practice the dose of haloperidol should only exceed 15mg/24 hours in exceptional circumstances

h. usual adult maximum dose of risperidone does not exceed 6mg/ 24 hours

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhs.uk/guidelines/scot.nhs.uk

2. Administration

2.1 *As required* psychotropic medications should only be administered for the prescribed indication and only where non-pharmacological approaches have failed or are inappropriate.

2.2 Where a patient is prescribed more than one *as required* psychotropic medication for the same indication, avoid administering combinations where possible and allow sufficient time to ascertain effect of first drug before administering another. (**Table 1: Pharmacokinetics of oral psychotropic medication**)

2.3 Ensure there is sufficient monitoring in place for potential adverse effects associated with the use of prescribed *as required* psychotropic medication.

2.4 Where *as required* oral psychotropic medication is used for management of acute behavioural disturbance, consideration must be given to monitoring physical observations using NEWS recorded on Patientrack. (**BAP recommends physical monitoring using the NEWS tool every hour for a minimum of one hour after the administration of oral psychotropic medication.**¹¹)

3. Documentation

3.1 All administration of *as required* psychotropic medication must be recorded on the prescribing and administration system (HEPMA).

3.2 All administration of *as required* psychotropic medication should be documented within the patient's clinical notes. Best practice would suggest that the following are considered and documented;

- Date and time of administration
- Medication and dose administered
- Reason for administration
- Details of any non-pharmacological approaches attempted prior to medication administration
- Details of the response to the intervention
- Details of any adverse effects noted
- Details of physical health monitoring undertaken where appropriate

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk

4. Review

- 4.1 There should be a regular review (at least weekly) of *as required* psychotropic medication as part of the multidisciplinary team meeting and evidence of this review should be documented in the clinical notes by the prescriber. Ongoing use of *as required* psychotropic medication without review potentially increases the risk of adverse effects e.g. falls risk in elderly, dependence and tolerance (with benzodiazepines).
- 4.2 Where there is ongoing use of *as required* psychotropic medication, there should be a review and consideration to optimisation of regular medication.
- 4.3 The ongoing need for *as required* psychotropic medication should be reviewed frequently. If *as required* medication has not been administered for 2 weeks, consider discontinuing, unless otherwise clinically indicated.
- 4.4 *As required* psychotropic medications should not be routinely prescribed for passes from hospital or on discharge.

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk

References/Evidence

1. NHS Lanarkshire Delirium Guidelines. May 2024.
https://www.rightdecisions.scot.nhs.uk/media/zyqpmeeh/delirium-guidelines-final-june-24-upload-vers_michael-cooper-2.pdf
2. Akram G et al. The administration of psychotropic prn medications in Scottish psychiatric intensive care units. *J Psych Int Car* 2014; 10(2): 64-74
3. Cochrane S et al. An audit of rapid tranquillisation in NHSL 2015
4. Fotedar M et al. An audit of *as required* medication in NHSL 2016
5. Mental Welfare Commission for Scotland. Medical Treatment under part 16 of the Mental Health (Care and Treatment) (Scotland) Act 2003. Advice Notes. April 2021
6. Mental Welfare Commission for Scotland. Consent to Treatment: A guide for Mental Health Practitioners. Good Practice Guide. Jan 2017
7. NHS Lanarkshire Code of Practice for Medicines Governance. April 2018
8. NHS Lanarkshire. High Dose Antipsychotic Treatment Guideline Jan 2025.
<https://www.rightdecisions.scot.nhs.uk/media/tdogte00/high-dose-antipsychotic-treatment-hdat-guideline.pdf>
9. NHS Lanarkshire. Guideline for Intramuscular Medication for Acute Behavioural Disturbance in MHLID inpatient services. *New date. New link*
10. Electronic Medicines Compendium. Summary of Product Characteristics.
www.medicines.org.uk
11. Martindale. The Complete Drug Reference. <https://www.medicinescomplete.com>
12. Patel et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. *Journal of Psychopharmacology* 2018;1-40
13. Specialist Pharmacy Service. Oral Benzodiazepines and choosing equivalent doses. Jul 2025 <https://www.sps.nhs.uk/articles/oral-benzodiazepines-and-choosing-equivalent-doses/>

Original version adapted from;

1. NHS GGC Best practice points for the prescribing, administration and recording of *as required* psychotropic drugs. Feb 2019
2. East London NHS Foundation Trust. Guidelines for the prescribing and administration of PRN psychotropic medicines. Sep 2017

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhs.uk/guidelines.scot.nhs.uk

Appendices

1. Governance information for Guidance document

Lead Author(s):	A Khamisya, A Ballantyne,
Endorsing Body:	Area Drug & Therapeutics Committee
Version Number:	3
Approval date	18/3/26
Review Date:	18/3/29
Responsible Person (if different from lead author)	L Templeton

CONSULTATION AND DISTRIBUTION RECORD	
Contributing Author / Authors	<ul style="list-style-type: none"> • M Abbas • L Templeton
Consultation Process / Stakeholders:	<ul style="list-style-type: none"> • Members of MHLDA D&T
Distribution	<ul style="list-style-type: none"> • Dissemination to all Nursing, medical and pharmacy staff working within Mental Health & Learning Disability inpatient services • NHSL clinical guideline website and app • MHLDA D&T newsletter

CHANGE RECORD			
Date	Lead Author	Change	Version
Apr 2019	MHLDA D&T	<i>New Guideline</i>	1
Aug 2022	L Templeton	<i>Formatting changes</i>	2
TBC	A Ballantyne A Khamisya	<i>Addition of risks and adverse effects of promethazine</i> <i>Cost effective prescribing added</i> <i>Benzodiazepine equivalence added</i> <i>Update on referenced guidelines</i> <i>Formatting changes including change of template</i>	3

Lead Author	A Khamisya	Date approved	18/3/26
Version	V3	Review Date	18/3/29

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk